Svetlana Nikic, Founder at Precision Oncology Consulting, shared a post by Frank Holtrup, Chief Technology Officer at Haystack Oncology, on LinkedIn, adding:
“Congratulations Haystack team, a Quest Diagnostics company for receiving breakthrough device designation by FDA for their MRD assay (aimed for use for stage II CRC patients).”
“Proud of the entire Haystack MRD™ by Quest Diagnostics® team for achieving this important milestone on our way to create a healthier world, one life at a time.”
More posts featuring Svetlana Nikic.